Ecopipam (SCH 39166) hydrobromide is a potent, selective and orally active antagonist of dopamine D1/D5 receptor , with K i s of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrobromide shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (K i =0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam hydrobromide can be used for the research of schizophrenia and obesity In Vitro Ecopipam (2 μM) hydrobromide completely abolishes the proconvulsive effect of Dopamine (10 μM) in isolated corticohippocampal formation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Ecopipam (10, mg/kg, oral administration) antagonizes Apomorphine-induced stereotypy in rats. Ecopipam (5 and 10 μM, perfusion, 1 μL/min) reversibly and dose-dependently decreases acetylcholine release in the rat striatum. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male young adult Long-Evans rats were injected with NicotineDosage: 0.003, 0.01, 0.03, 0.1, 0.3 mg/kg Administration: A single s.c. 20 min before Nicotine (0.1 mg/kg) Result: Dose-dependently reduced pressing on both active and inactive levers. Form:Solid IC50& Target:D 1 Receptor 1.2 nM (Ki) D 5 Receptor 2.0 nM (Ki) D 2 Receptor 980 nM (Ki) D 4 Receptor 5520 nM (Ki) 5-HT Receptor 80 nM (Ki) Alpha-2A adrenergic receptor 731 nM (Ki)